# Assess Safety and Compare PK of New Oral hPTH(1-34) Tablet Formulations vs. EBP05 Tablets and Subcutaneous Forteo

> **NCT05965167** · PHASE1 · COMPLETED · sponsor: **Entera Bio Ltd.** · enrollment: 45 (actual)

## Conditions studied

- Hypoparathyroidism
- Osteoporosis
- Fractures, Bone
- Other Disease

## Interventions

- **DRUG:** EBP05
- **DRUG:** Forteo 0.02 mg
- **DRUG:** EBP11
- **DRUG:** EBP22
- **DRUG:** EBP11-F2
- **DRUG:** EBP11-F4
- **DRUG:** EBP11-F1
- **DRUG:** EBP11-F5

## Key facts

- **NCT ID:** NCT05965167
- **Lead sponsor:** Entera Bio Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-05-11
- **Primary completion:** 2026-02-08
- **Final completion:** 2026-02-08
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2026-02-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05965167

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05965167, "Assess Safety and Compare PK of New Oral hPTH(1-34) Tablet Formulations vs. EBP05 Tablets and Subcutaneous Forteo". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT05965167. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*